The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The MagnetisMM-20 trial of elranatamab with carfilzomib and dexamethasone in RRMM
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, comments on the impressive efficacy of elranatamab in combination with carfilzomib and dexamethasone in the Phase Ib MagnetisMM-20 trial (NCT05675449) in relapsed/refractory multiple myeloma (RRMM). He reports an overall response rate of 100% and a complete response rate of 75%. Prof. Landgren notes that further expansion and longer follow-ups are needed to confirm these results. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
At ASH 2024 in San Diego, we had the pleasure of presenting the MagnetisMM-20 data. This is the Phase Ib study combining elranatamab, the BCMA CD3 bispecific antibody with carfilzomib and dexamethasone. We have seen how these bispecific antibodies work very well as single agents. The first data suggests over 60 plus percent of patients with an overall response. But we all know that combinations with different drugs is usually how myeloma is best treated for long, durable, successful patients...
At ASH 2024 in San Diego, we had the pleasure of presenting the MagnetisMM-20 data. This is the Phase Ib study combining elranatamab, the BCMA CD3 bispecific antibody with carfilzomib and dexamethasone. We have seen how these bispecific antibodies work very well as single agents. The first data suggests over 60 plus percent of patients with an overall response. But we all know that combinations with different drugs is usually how myeloma is best treated for long, durable, successful patients. So what’s the optimal partner drug for a BCMA CD3 bispecific antibody? The MagnetisMM-20 study used, as I mentioned, carfilzomib. The Phase Ib data was presented by my colleague, Dr. Michael Thomason, and I was the senior author for the presentation. Overall response rates are 100%. So it doesn’t get better than 100%. If you look at the CR rates, the complete response rates, it was 75%. And the VGPR rates are better, over 91%. So very impressive efficacy results. Looking at safety, there was really no new safety signal from what we have seen and compared to prior studies using carfilzomib or using elranatamab. So there was no new interactions or triggering of anything that we had not seen before. So overall, I would say this is a success. The study is a Phase Ib study. So it’s a step up dosing and the cohorts are quite small. So what needs to happen next is expanding the numbers and to have longer follow up. And that will happen in the coming future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Takeda: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Theradex: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.; Amgen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Merck: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Adaptive: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.
